Douglas Laux, MD
Hematology & Oncology · Iowa City, IANPI 1295946218
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,647 of the $3,647 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Sanofi.
Across 1 payment — averaging $3647.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
Across 344 payments — averaging $9477.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Regeneron$844K
- Pfizer$265K
- Ascendis Pharma Endocrinology Inc$224K
- GSK$194K
- E.r. Squibb & Sons, L.L.C.$188K
- plus $142K from 4 others
What the payments were for
- Consulting fees$3,647100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $3,647 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$3,647
How this compares
$3,647 in reported general payments places this provider in the 75th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 60 | $1,369,810 |
| RetevmoSelpercatinib | 19 | $517,169 |
| ErivedgeVismodegib | 17 | $220,133 |
| EliquisApixaban | 43 | $23,537 |
| Ondansetron Hcl | 69 | $5,776 |
| Gabapentin | 78 | $2,594 |
| Levothyroxine Sodium | 283 | $1,868 |
| Escitalopram Oxalate | 14 | $1,423 |
| Hydrocortisone | 30 | $919 |
| Oxycodone Hcl | 48 | $897 |
| SynthroidLevothyroxine Sodium | 16 | $747 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $676 |
| Prochlorperazine Maleate | 54 | $647 |
| Duloxetine Hcl | 96 | $514 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $497 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Iowa City
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Mohammed MilhemIowa City$8K
- Laurel LyckholmIowa City$7K
- Christopher StrouseIowa City$7K
- Seth MaliskeIowa City$6K
- Varun MongaIowa City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.